Immix Biopharma (IMMX) Liabilities and Shareholders Equity (2020 - 2026)

Immix Biopharma has disclosed Liabilities and Shareholders Equity across 7 years of filings, most recently posting $95.8 million for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $95.8 million, up 381.68% year-over-year; the trailing twelve-month figure through Mar 2026 was $236.4 million (up 144.14% YoY), and the FY2025 annual result was $104.8 million, up 356.86% from the prior year.
• Liabilities and Shareholders Equity came in at $95.8 million for Q1 2026 at Immix Biopharma, down from $104.8 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $104.8 million in Q4 2025 to a low of $13.2 million in Q1 2023.
• The 5-year median for Liabilities and Shareholders Equity is $20.0 million (2022), against an average of $30.0 million.
• Across the five-year window, Liabilities and Shareholders Equity plunged 45.78% in 2025 and surged 381.68% in 2026, its largest moves.
• Immix Biopharma's Liabilities and Shareholders Equity stood at $14.9 million in 2022, then jumped by 33.65% to $19.9 million in 2023, then advanced by 15.17% to $22.9 million in 2024, then jumped by 356.86% to $104.8 million in 2025, then decreased by 8.61% to $95.8 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $95.8 million (Q1 2026), $104.8 million (Q4 2025), and $20.1 million (Q3 2025), per Business Quant data.